Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Video / Webinar Healthcare Australia's Private Healthcare Sector: Strategic Outlook and Opportunities October 6, 2025
Video / Webinar Life Sciences & Pharma Navigating China's Volume-Based Procurement in the Pharma Industry August 27, 2025
Executive Insights Life Sciences & Pharma Unlocking Brazil’s Clinical Trial Opportunity: A Strategic Roadmap for Healthcare Leaders August 18, 2025
Special Report Life Sciences & Pharma Prescription for Progress: A Health Equity Maturity Framework for Pharma Companies June 12, 2025
Executive Insights Life Sciences & Pharma Advanced In Vitro Models: Opportunities and Challenges for US Drug Development May 7, 2025
Case Study Life Sciences & Pharma Global Manufacturing Footprint Rationalization for a Leading Biopharmaceutical Company March 31, 2025 A leading biopharmaceutical company engaged L.E.K. Consulting to optimize its global manufacturing network. The client sought to reduce costs while…
